NASDAQ:GHDX - Genomic Health Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $68.28 -0.04 (-0.06 %) (As of 10/18/2018 10:25 AM ET)Previous Close$68.32Today's Range$67.70 - $68.4952-Week Range$26.54 - $72.83Volume1,143 shsAverage Volume262,181 shsMarket Capitalization$2.52 billionP/E Ratio6,850.00Dividend YieldN/ABeta0.45 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The company offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit. It also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer; the Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk disease, as well as used to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score or tumor grading; and Oncotype DX AR-V7 Nucleus Detect test for men with metastatic castration-resistant prostate cancer. The company offers its products through a network of distributors. Genomic Health, Inc. has collaboration agreement with Epic Sciences, Inc.; license and development agreement with Biocartis N.V.; license agreement with Cleveland Diagnostics, Inc.; and a research collaboration agreement with Janssen Pharmaceuticals. The company was founded in 2000 and is based in Redwood City, California. Receive GHDX News and Ratings via Email Sign-up to receive the latest news and ratings for GHDX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryBiotechnology SectorMedical SymbolNASDAQ:GHDX CUSIP37244C10 Webwww.genomichealth.com Phone650-556-9300 Debt Debt-to-Equity RatioN/A Current Ratio5.39 Quick Ratio5.39 Price-To-Earnings Trailing P/E Ratio6,850.00 Forward P/E Ratio126.44 P/E GrowthN/A Sales & Book Value Annual Sales$340.75 million Price / Sales7.18 Cash Flow$0.3392 per share Price / Cash201.30 Book Value$5.41 per share Price / Book12.62 Profitability EPS (Most Recent Fiscal Year)$0.01 Net Income$-3,850,000.00 Net Margins1.18% Return on Equity9.09% Return on Assets7.41% Miscellaneous Employees863 Outstanding Shares35,850,000Market Cap$2.52 billion Genomic Health (NASDAQ:GHDX) Frequently Asked Questions What is Genomic Health's stock symbol? Genomic Health trades on the NASDAQ under the ticker symbol "GHDX." How were Genomic Health's earnings last quarter? Genomic Health, Inc. (NASDAQ:GHDX) released its quarterly earnings results on Thursday, August, 2nd. The medical research company reported $0.26 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.07 by $0.19. The medical research company had revenue of $95.60 million for the quarter, compared to analysts' expectations of $92.23 million. Genomic Health had a net margin of 1.18% and a return on equity of 9.09%. Genomic Health's revenue was up 14.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.08) earnings per share. View Genomic Health's Earnings History. When is Genomic Health's next earnings date? Genomic Health is scheduled to release their next quarterly earnings announcement on Wednesday, November 14th 2018. View Earnings Estimates for Genomic Health. What guidance has Genomic Health issued on next quarter's earnings? Genomic Health issued an update on its FY18 earnings guidance on Thursday, August, 2nd. The company provided earnings per share guidance of $0.39-0.56 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.45. The company issued revenue guidance of $366-382 million, compared to the consensus revenue estimate of $377.43 million. What price target have analysts set for GHDX? 9 analysts have issued 1 year price targets for Genomic Health's shares. Their forecasts range from $25.00 to $62.00. On average, they expect Genomic Health's stock price to reach $42.75 in the next twelve months. This suggests that the stock has a possible downside of 37.4%. View Analyst Price Targets for Genomic Health. What is the consensus analysts' recommendation for Genomic Health? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genomic Health in the last year. There are currently 2 sell ratings, 6 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Genomic Health. Are investors shorting Genomic Health? Genomic Health saw a increase in short interest in September. As of September 28th, there was short interest totalling 958,498 shares, an increase of 90.4% from the September 14th total of 503,528 shares. Based on an average daily trading volume, of 361,338 shares, the short-interest ratio is currently 2.7 days. Approximately 2.7% of the company's stock are sold short. View Genomic Health's Current Options Chain. Who are some of Genomic Health's key competitors? Some companies that are related to Genomic Health include Foundation Medicine (FMI), ELEKTA AB/ADR (EKTAY), Natera (NTRA), InVitae (NVTA), CareDx (CDNA), RadNet (RDNT), Veracyte (VCYT), Celcuity (CELC), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), PotNetwork (POTN), Psychemedics (PMD), Fulgent Genetics (FLGT), First Choice Healthcare Solutions (FCHS) and Cancer Genetics (CGIX). Who are Genomic Health's key executives? Genomic Health's management team includes the folowing people: Ms. Kimberly J. Popovits, Chairman, CEO & Pres (Age 59)Dr. Steven Shak, Co-Founder, Chief Scientific Officer & Chief Medical Officer (Age 67)Mr. G. Bradley Cole, Chief Financial Officer (Age 62)Dr. Frederic G. Pla, Chief Operating Officer (Age 59)Mr. James J. Vaughn, Chief U.S. Commercial Officer (Age 55) Who are Genomic Health's major shareholders? Genomic Health's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Scout Investments Inc. (0.22%), Aurora Investment Counsel (0.12%), Bank of Montreal Can (0.11%) and MERIAN GLOBAL INVESTORS UK Ltd (0.02%). Company insiders that own Genomic Health stock include Fred E Cohen, Frederic Pla, G Bradley Cole, James J Vaughn, Kimberly J Popovits, Laura Leber, Phillip G Febbo and Steven Shak. View Institutional Ownership Trends for Genomic Health. Which institutional investors are selling Genomic Health stock? GHDX stock was sold by a variety of institutional investors in the last quarter, including Aurora Investment Counsel. Company insiders that have sold Genomic Health company stock in the last year include Fred E Cohen, Frederic Pla, G Bradley Cole, James J Vaughn, Kimberly J Popovits, Laura Leber, Phillip G Febbo and Steven Shak. View Insider Buying and Selling for Genomic Health. Which institutional investors are buying Genomic Health stock? GHDX stock was purchased by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, Bank of Montreal Can and Scout Investments Inc.. View Insider Buying and Selling for Genomic Health. How do I buy shares of Genomic Health? Shares of GHDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Genomic Health's stock price today? One share of GHDX stock can currently be purchased for approximately $68.32. How big of a company is Genomic Health? Genomic Health has a market capitalization of $2.52 billion and generates $340.75 million in revenue each year. The medical research company earns $-3,850,000.00 in net income (profit) each year or $0.01 on an earnings per share basis. Genomic Health employs 863 workers across the globe. What is Genomic Health's official website? The official website for Genomic Health is http://www.genomichealth.com. How can I contact Genomic Health? Genomic Health's mailing address is 301 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The medical research company can be reached via phone at 650-556-9300 or via email at [email protected] MarketBeat Community Rating for Genomic Health (NASDAQ GHDX)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 249 (Vote Outperform)Underperform Votes: 313 (Vote Underperform)Total Votes: 562MarketBeat's community ratings are surveys of what our community members think about Genomic Health and other stocks. Vote "Outperform" if you believe GHDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GHDX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/18/2018 by MarketBeat.com StaffFeatured Article: How can investors find ex-dividend dates?